Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02142933
Other study ID # EKNZ-2014-087
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2014
Est. completion date March 2017

Study information

Verified date June 2018
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

1. At the University Hospital Basel, Switzerland, a simplified screening for group B streptococci (GBS) of vagina and perineum has been performed since several years. Reliable detection of GBS is critical to prevent GBS transmission during delivery with antimicrobial prophylaxis. Transmission of GBS to the neonate may otherwise lead to severe infection and complications in the neonate. Centers for Disease Control and Prevention (CDC) and other international organizations recommend a vaginal and additional rectal swab.We therefore aim to test this simplified screening against the international gold standard.

2. Antibiotic resistant bacteria may reside in the genital tract of an expected mother and may be transmitted to the new-born during delivery. In case of infection of the pregnant woman or the neonate, application of standard antimicrobial treatment will insufficiently cover these extended spectrum beta-lactamase (ESBL) producing bacteria. Therefore, colonization with ESBL in pregnancy needs to be known to potentially deliver adequate antimicrobial treatment.


Description:

Transmission of GBS under delivery leads in 1/1000 of live births to severe sepsis in the neonate and may have serious sequelae including death. Most of the cases concern early onset sepsis which occurs in the first three to seven days after birth. Several randomized studies showed that antibiotic prophylaxis during delivery reduces the risk of early onset sepsis in the neonate in 85%, whereas late onset sepsis was not affected. Accurate screening including appropriate culture methods are critical for the wealth of the newborn and the decision regarding application of antibiotic prophylaxis to the mother. In this study we compare a simplified test algorithm taking swabs from the vagina and the perineum only versus a combined vaginal and rectal swab for GBS culture which is the current gold standard of diagnosis as the culture yield for GBS increases substantially when samples are taken from both the lower vagina and the rectum compared to swabbing the vagina or endocervix only. There is certain reluctance for performing a rectal swab as it has been associated with discomfort.

The study aims to demonstrate that this simplified vagino-perineal swab leads to a similar GBS detection rate as compared to the gold standard comprising of a combined vaginal and rectal swab. We further aim to systematically assess the degree of discomfort with the rectal swab and compare the costs when applying those different methods.

Additionally we aim to determine the prevalence and risk factors of community acquired ESBL by further processing the swabs in the appropriate culture media and filling in a standardized questionnaire.

We plan a prospective cohort study with inclusion of 450 pregnant women who attend the outpatient obstetric clinic for routine control in the third trimester.


Recruitment information / eligibility

Status Completed
Enrollment 250
Est. completion date March 2017
Est. primary completion date November 2016
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- third trimester pregnancy

- must attend clinic for routine screening for group B streptococcus (GBS)

Exclusion Criteria:

- detection of group B streptococcus in urine

- history of neonatal group B streptococcal sepsis in previous pregnancy

- antibiotic treatment within the past 2 weeks before routine GBS screening

- delivery < 37 gestational week

- condition or disorders suggestive for urinary tract infection, genital tract infection, or bacterial vaginosis

- language barrier (insufficient knowledge of German or English)

- the expected mother has any other condition, that, in the opinion of the investigator or treating physician, would jeopardize the safety or rights of the expected mother participating in the study, or would confound the results of the study

Study Design


Intervention

Other:
vagino-perineal swab


Locations

Country Name City State
Switzerland University Hospital Basel Basel

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland Stiftung Forschung Infektionskrankheiten, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Other Evaluation of costs for additional rectal swab On routine visit in third trimester pregnancy between 38 and 42 gestational week
Other Resistance pattern of ESBL bacteria between 38 and 42 gestational week
Primary Presence of group B streptococci in genital tract on routine visit in third trimester of pregnancy third trimester of pregnancy
Primary Presence of colonizing extended-spectrum beta-lactamase enterobacteriaceae in genital tract on routine visit in third trimester pregnancy third trimester of pregnancy
Secondary Evaluation of pain during performance of rectal swab On routine visit in third trimester pregnancy third trimester of pregnancy
Secondary Evaluation of discomfort during performance of rectal swab On routine visit in third trimester pregnancy third trimester of pregnancy
Secondary Evaluation of stress during performance of rectal swab On routine visit in third trimester pregnancy third trimester of pregnancy
Secondary risk factors for ESBL carriage on routine visit in third trimester of pregnancy third trimester of pregnancy
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05832502 - Clinical Trial Investigating the Safety and Immunogenicity of GBS6 in Pregnant Women With and Without HIV (PREPARE) Phase 2
Completed NCT04596878 - Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV Phase 2
Withdrawn NCT04116645 - Time Frame for GBS Screening
Terminated NCT02814318 - Intrapartum Effect of Vancomycin on Rectovaginal GBS Colonization
Withdrawn NCT04227730 - MATERNAL AND NEONATAL SCREENING FOR GROUP B STREPTOCOCCI : A Follow up STUDY
Completed NCT05154578 - Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women Phase 2
Completed NCT02528981 - Effect of Probiotics on GBS Colonization Status During Pregnancy: A Pilot Randomized Controlled Trial N/A
Recruiting NCT01577108 - Oral Probiotics Reduce Group B Streptococci Colonization in Pregnant Women Phase 2